ADIAL PHARMACEUTICALS INC (ADIL) Stock Analyst Earnings Estimates
NASDAQ:ADIL - Nasdaq - US00688A2050 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 104.34% | N/A 64.08% | N/A 44.36% | N/A 27.38% | ||||||||||
| EBITDA YoY % growth | -800K | -410K 48.75% | -1M -143.90% | -6.99M -599.00% | -8.24M -17.88% | -10.93M -32.65% | -17.73M -62.21% | -13.31M 24.93% | -6.887M 48.25% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -800K | -410K 48.75% | -1M -143.90% | -6.99M -599.00% | -8.24M -17.88% | -10.93M -32.65% | -17.74M -62.31% | -13.32M 24.92% | -6.888M 48.29% | N/A -23.30% | N/A -14.06% | N/A -71.14% | N/A -27.85% | N/A 92.49% | N/A 1,346.56% | N/A 190.06% | N/A 59.29% | N/A 23.69% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | -0.86 | N/A -2,746.51% | -13.00 46.90% | -4.32 66.77% | N/A 29.80% | N/A 55.44% | N/A -3.40% | N/A 5.11% | N/A 93.85% | N/A 1,375.00% | N/A 188.24% | N/A 58.84% | N/A 23.13% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.39 71.29% | -0.41 34.19% | -0.32 46.41% | -0.32 16.79% | -0.32 18.42% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.06M -15.48% | -2.448M -32.68% | -1.887M 17.50% | -1.887M 14.67% | -1.887M 8.40% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.38 67.80% | -0.45 | 0.07 | 15.33% |
| Q2 2024 Q2Q % growth | -0.59 -161.46% | -0.55 | -0.04 | -8.12% |
| Q1 2024 Q2Q % growth | -0.62 77.45% | -0.34 | -0.28 | -84.19% |
| Q4 2023 Q2Q % growth | -1.35 50.91% | -0.78 | -0.57 | -74.15% |
| Q3 2023 Q2Q % growth | -1.18 60.67% | -1.16 | -0.02 | -1.93% |
| Q2 2023 Q2Q % growth | 0.96 124.00% | -1.53 | 2.49 | 162.75% |
| Q1 2023 Q2Q % growth | -2.75 15.38% | -3.57 | 0.82 | 22.97% |
| Q4 2022 Q2Q % growth | -2.75 60.85% | -3.83 | 1.08 | 28.10% |
| Q3 2022 Q2Q % growth | -3.00 -1,263.64% | -4.59 | 1.59 | 34.64% |
| Q2 2022 Q2Q % growth | -4.00 -1,500.00% | -3.70 | -0.30 | -8.18% |
| Q1 2022 Q2Q % growth | -3.25 -2,024.18% | -4.34 | 1.09 | 25.03% |
| Q4 2021 Q2Q % growth | -7.03 -2,827.08% | -5.27 | -1.75 | -33.30% |
| Q3 2021 Q2Q % growth | -0.22 8.33% | -0.22 | 0.00 | 1.96% |
| Q2 2021 Q2Q % growth | -0.25 -56.25% | -0.21 | -0.04 | -19.56% |
| Q1 2021 Q2Q % growth | 30.45% | -0.15 | % | |
| Q4 2020 Q2Q % growth | -0.24 | -0.26 | 0.02 | 5.88% |
| Q3 2020 Q2Q % growth | -0.24 -41.18% | -0.18 | -0.06 | -30.72% |
| Q2 2020 Q2Q % growth | -0.16 23.81% | -0.18 | 0.02 | 12.85% |
| Q1 2020 Q2Q % growth | -0.22 18.52% | % | ||
| Q2 2019 Q2Q % growth | -0.21 | -0.18 | -0.03 | -14.38% |
| Q1 2019 Q2Q % growth | -0.27 | -0.17 | -0.10 | -55.71% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 9.52% | 7.32% | 0% | 2.09% |
| Revenue | N/A | N/A | N/A | N/A |